MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Pfizer

Atidarymo kaina

SektoriusSveikatos priežiūra

22.85 0.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.5

Max

22.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.1B

411M

Pardavimai

63M

18B

P/E

Sektoriaus vid.

15.631

57.333

Pelnas, tenkantis vienai akcijai

0.63

Dividendų pajamingumas

7.8

Pelno marža

2.314

Darbuotojai

81,000

EBITDA

-4.3B

2.5B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+22.04% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

7.80%

2.63%

Kitas uždarbis

2025-04-29

Kitas dividendų mokėjimo data

2025-06-13

Kita Ex Dividend data

2025-05-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-26B

126B

Ankstesnė atidarymo kaina

22.23

Ankstesnė uždarymo kaina

22.85

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-14 11:09; UTC

Pagrindinės rinkos jėgos

Pfizer Shares Slip After Company Scraps Weight-Loss Pill

2025-04-09 18:18; UTC

Pagrindinės rinkos jėgos

Pharma Shares Reverse Losses After Tariff Pause

2025-04-09 09:39; UTC

Pagrindinės rinkos jėgos

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025-03-19 07:34; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

2025-03-18 17:26; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer to Dispose of Remaining Shareholding in Haleon

2025-04-14 14:36; UTC

Svarbiausios naujienos

Pfizer Halts Development of Weight-Loss Pill -- Update

2025-04-14 14:14; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

2025-04-14 10:45; UTC

Svarbiausios naujienos

Pfizer Halts Development of Weight-Loss Pill -- WSJ

2025-04-08 21:26; UTC

Uždarbis

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2025-03-26 22:29; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

2025-03-26 19:19; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

2025-03-26 17:39; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

2025-03-18 16:58; UTC

Įsigijimai, susijungimai, perėmimai

Haleon Intends to Cancel Purchased Ordinary Shares

2025-03-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

2025-03-18 16:56; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

2025-03-18 16:56; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

2025-03-18 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Haleon Takes Note of Announcement

2025-03-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

2025-03-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: This Is Subject to Customary Closing Conditions

2025-03-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

2025-03-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

2025-03-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Bookbuilding Period Will Commence Immediately

2025-03-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

2025-03-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

2025-03-18 16:47; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup:: Amount Is Pfizer's Entire Residual Shareholding in Haleon

2025-03-18 16:47; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: This Represents Approx 7.3% Stake in Haleon

2025-03-18 16:46; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup: Pfizer Intends to Sell Approx 662M Ordinary Shares in Haleon

2025-03-17 09:00; UTC

Svarbiausios naujienos

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-14 11:38; UTC

Svarbiausios naujienos
Uždarbis

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

22.04% į viršų

12 mėnesių prognozė

Vidutinis 27.8 USD  22.04%

Aukščiausias 32 USD

Žemiausias 23 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

5

Pirkti

12

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

22.12 / 23.055Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.